| 1 |
33954816 | Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. | 2022 Mar |
1 |
| 2 |
35236053 | Decitabine salvage for Tumor Protein P53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. | 2022 Mar 3 |
1 |
| 3 |
35237000 | Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation. | 2022 Feb |
1 |
| 4 |
33321328 | HPV-inactive cell populations arise from HPV16-transformed human keratinocytes after p53 knockout. | 2021 Feb |
1 |
| 5 |
33399480 | Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. | 2021 Jun |
1 |
| 6 |
33627797 | Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations. | 2021 Jul |
1 |
| 7 |
33932107 | Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. | 2021 May |
1 |
| 8 |
34226168 | Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS - A Multicenter, Retrospective Study. | 2021 Oct |
1 |
| 9 |
34534222 | 5-aza-2'-deoxycytidine induces apoptosis and inhibits tumour growth in vivo of FaDu cells, a specific HPVnegative HNSCC cell line. | 2021 |
2 |
| 10 |
34841700 | Decitabine activates type I interferon signaling to inhibit p53-deficient myeloid malignant cells. | 2021 Nov |
1 |
| 11 |
32030889 | TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype. | 2020 Jun |
2 |
| 12 |
32504186 | Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. | 2020 Jul |
3 |
| 13 |
33001991 | Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. | 2020 |
3 |
| 14 |
33323826 | Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation. | 2020 Dec 8 |
1 |
| 15 |
30792212 | TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies. | 2019 Aug |
2 |
| 16 |
31418371 | [Inducing Effect of Decitabine on Apoptosis of KMS-18 Myeloma Cells and Its Mechanism]. | 2019 Aug |
3 |
| 17 |
29735783 | Antiproliferative Effects of Epigenetic Modifier Drugs Through E-cadherin Up-regulation in Liver Cancer Cell Lines. | 2018 May-June |
1 |
| 18 |
29877251 | [Biomarkers predicting the efficacy of DNA hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia: TET enzymes]. | 2018 |
1 |
| 19 |
30466751 | Patterns of mutations in TP53 mutated AML. | 2018 Dec |
1 |
| 20 |
30501707 | [Clinical Efficacy and Prognostic Factors of Decitabine for Treatment of Myelodysplastic Syndrome]. | 2018 Dec |
2 |
| 21 |
27984642 | TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. | 2017 Feb |
2 |
| 22 |
27995947 | Haematological cancer: TP53 mutations sensitize to decitabine. | 2017 Feb |
1 |
| 23 |
28129641 | The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA. | 2017 Jan 31 |
1 |
| 24 |
28225682 | Decitabine in TP53-Mutated AML. | 2017 Feb 23 |
1 |
| 25 |
28229579 | Decitabine in TP53-Mutated AML. | 2017 Feb 23 |
1 |
| 26 |
28453190 | Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines. | 2017 Aug |
1 |
| 27 |
28484169 | Current diagnosis and treatment for myelodysplastc syndromes. | 2017 |
2 |
| 28 |
28802167 | Induction of senescence in cancer cells by 5'-Aza-2'-deoxycytidine: Bioinformatics and experimental insights to its targets. | 2017 Oct |
2 |
| 29 |
29143344 | Down-regulation of p16 and MGMT promotes the anti-proliferative and pro-apoptotic effects of 5-Aza-dC and radiation on cervical cancer cells. | 2017 Dec |
1 |
| 30 |
25409339 | Treatment of buffalo (Bubalus bubalis) donor cells with trichostatin A and 5-aza-2'-deoxycytidine alters their growth characteristics, gene expression and epigenetic status and improves the in vitro developmental competence, quality and epigenetic status of cloned embryos. | 2016 Apr |
1 |
| 31 |
26258493 | Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status. | 2016 Sep |
1 |
| 32 |
27959731 | TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. | 2016 Nov 24 |
1 |
| 33 |
25621498 | Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. | 2015 Mar 2 |
1 |
| 34 |
25751281 | Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. | 2015 Apr 6 |
1 |
| 35 |
26384351 | The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. | 2015 Oct 20 |
1 |
| 36 |
24676336 | Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI. | 2014 May |
1 |
| 37 |
25140197 | Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells. | 2014 |
1 |
| 38 |
23079745 | Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. | 2013 Mar |
1 |
| 39 |
23201008 | Cytotoxicity of 5-Aza-2'-deoxycytidine against gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of P16(INK4A). | 2013 Feb |
1 |
| 40 |
23582784 | Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. | 2013 May |
8 |
| 41 |
23810988 | Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells. | 2013 Aug 15 |
1 |
| 42 |
24163369 | Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter. | 2013 Dec 13 |
2 |
| 43 |
24319226 | Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. | 2013 |
1 |
| 44 |
21455989 | The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. | 2012 Mar 1 |
2 |
| 45 |
22429346 | Targeted drug regulation on methylation of p53-BAX mitochondrial apoptosis pathway affects the growth of cholangiocarcinoma cells. | 2012 |
2 |
| 46 |
23141446 | [Inhibition of human laryngeal carcinoma growth by gene therapy and epigenetic therapy]. | 2012 Sep |
1 |
| 47 |
23300844 | Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. | 2012 |
1 |
| 48 |
21550660 | Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells. | 2011 Jul |
3 |
| 49 |
21701495 | p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. | 2011 Nov |
2 |
| 50 |
21725200 | The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression. | 2011 Aug |
2 |